Editor's Highlights-June 2025.

Abstract

Advances in inflammatory skin disease management are rapidly redefining dermatologic practice.

This issue presents a compelling framework unifying type 2 inflammation across conditions like atopic dermatitis, prurigo nodularis, and chronic urticaria, emphasizing shared cytokine pathways and therapeutic opportunities.

Also featured here is new real-world evidence supporting dupilumab efficacy following tralokinumab failure. In psoriasis, a novel "step-down" treatment strategy advocates for earlier biologic use in younger patients, followed by de-escalation.

A paired commentary tempers this proposal with methodological and practical concerns. Finally, data on bimekizumab's safety and effectiveness in patients with chronic kidney disease address a critical clinical gap.

These contributions highlight a shift toward precision medicine, integrating immunologic insight with patient age, comorbidity profiles, and therapeutic sequencing to inform truly individualized care.

References:

R. Chovatiya, A. Al‐Dabagh, M. Amin, R. Bissonnette, and E. Guttman‐Yassky, “Type 2 Inflammation and Its Role in Dermatologic Diseases,” International Journal of Dermatology 64, no. 6 (2025), https://doi.org/10.1111/ijd.17707.
L. Potestio, C. Brescia, C. Patruno, and M. Napolitano, “The Efficacy of Dupilumab in Patients Affected by Atopic Dermatitis Who Previously Failed Tralokinumab,” International Journal of Dermatology 64 (2025): 6, https://doi.org/10.1111/ijd.17611.
Y. Behlock, C. Dandoy, F. Willaert, et al., “Early Use of Beneficial Biological Therapy on Younger Psoriasis Patients: Could a ‘Step‐Down’ Therapy Approach be More Effective?,” International Journal of Dermatology 64 (2025): 6, https://doi.org/10.1111/ijd.17704.
H. Daungsupawong and V. Wiwanitkit, “Early Biologic Therapy in Young Psoriasis Patients: Evaluating the Step‐Down Approach,” International Journal of Dermatology 64 (2025): 6, https://doi.org/10.1111/ijd.17757.
Z. Fratton, A. Balato, S. Bighetti, et al., “Real‐World Experience Using Bimekizumab in a Patient Cohort With Plaque‐Type Psoriasis and Chronic Kidney Disease: A 48‐Week Retrospective Multicentre Study,” International Journal of Dermatology 64 (2025): 6, https://doi.org/10.1111/ijd.17657.

Article info

Journal issue:

Volume: not provided
Issue: not provided

Doi:

10.1111/ijd.17836

More resources:

Wiley

Full Text Sources

Paid

NCI CPTAC Assay Portal

Miscellaneous

Free resource

Editor's Highlights-June 2025.

Abstract

Advances in inflammatory skin disease management are rapidly redefining dermatologic practice.

References:

R. Chovatiya, A. Al‐Dabagh, M. Amin, R. Bissonnette, and E. Guttman‐Yassky, “Type 2 Inflammation and Its Role in Dermatologic Diseases,” International Journal of Dermatology 64, no. 6 (2025), https://doi.org/10.1111/ijd.17707.
L. Potestio, C. Brescia, C. Patruno, and M. Napolitano, “The Efficacy of Dupilumab in Patients Affected by Atopic Dermatitis Who Previously Failed Tralokinumab,” International Journal of Dermatology 64 (2025): 6, https://doi.org/10.1111/ijd.17611.
Y. Behlock, C. Dandoy, F. Willaert, et al., “Early Use of Beneficial Biological Therapy on Younger Psoriasis Patients: Could a ‘Step‐Down’ Therapy Approach be More Effective?,” International Journal of Dermatology 64 (2025): 6, https://doi.org/10.1111/ijd.17704.
H. Daungsupawong and V. Wiwanitkit, “Early Biologic Therapy in Young Psoriasis Patients: Evaluating the Step‐Down Approach,” International Journal of Dermatology 64 (2025): 6, https://doi.org/10.1111/ijd.17757.
Z. Fratton, A. Balato, S. Bighetti, et al., “Real‐World Experience Using Bimekizumab in a Patient Cohort With Plaque‐Type Psoriasis and Chronic Kidney Disease: A 48‐Week Retrospective Multicentre Study,” International Journal of Dermatology 64 (2025): 6, https://doi.org/10.1111/ijd.17657.